血管新生阻害剤および刺激剤の世界市場:市場規模・現状・予測(2019-2025)

QYResearchが発行した調査報告書(QYR9050412)
◆英語タイトル:Global Angiongenesis Inhibitors and Stimulators Market Size, Status and Forecast 2019-2025
◆商品コード:QYR9050412
◆発行会社(リサーチ会社):QYResearch
◆発行日:2019年8月7日(※2024年版があります。お問い合わせください。)
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療・製薬・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Enterprise(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当資料は、血管新生阻害剤および刺激剤のグローバル市場について調査・分析したレポートで、種類別(血管新生、重積性血管新生)、用途別(病院、診療所、その他)、主要地域別(アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米)の市場規模、市場予測、関連企業情報などが含まれています。

・血管新生阻害剤および刺激剤の世界市場規模
・主要企業別市場シェア
・血管新生阻害剤および刺激剤の世界市場規模:種類別(血管新生、重積性血管新生)
・血管新生阻害剤および刺激剤の世界市場規模:用途別(病院、診療所、その他)
・血管新生阻害剤および刺激剤のアメリカ市場規模(種類別、用途別)
・血管新生阻害剤および刺激剤のヨーロッパ市場規模(種類別、用途別)
・血管新生阻害剤および刺激剤の中国市場規模(種類別、用途別)
・血管新生阻害剤および刺激剤の日本市場規模(種類別、用途別)
・血管新生阻害剤および刺激剤の東南アジア市場規模(種類別、用途別)
・血管新生阻害剤および刺激剤のインド市場規模(種類別、用途別)
・血管新生阻害剤および刺激剤の中南米市場規模(種類別、用途別)
・主要企業別分析(企業概要、製品動向、販売量など)
・血管新生阻害剤および刺激剤の世界市場予測(2019年-2025年)
・血管新生阻害剤および刺激剤の地域別市場予測(2019年-2025年)
...
【レポートの概要】

In 2018, the global Angiongenesis Inhibitors and Stimulators market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Angiongenesis Inhibitors and Stimulators status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Angiongenesis Inhibitors and Stimulators development in United States, Europe and China.

The key players covered in this study
Abbott Laboratories
Adnexus Therapeutics
F. Hoffman-La Roche
Genentech
Amgen
AstraZeneca
Novartis
Pfizer
Chugai Pharmaceutical
EntreMed
Eyetech

Market segment by Type, the product can be split into
Sprouting Angiogenesis
Intussusceptive Angiogenesis

Market segment by Application, split into
Hospitals
Clinics
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Angiongenesis Inhibitors and Stimulators status, future forecast, growth opportunity, key market and key players.
To present the Angiongenesis Inhibitors and Stimulators development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Angiongenesis Inhibitors and Stimulators are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Angiongenesis Inhibitors and Stimulators Market Size Growth Rate by Type (2014-2025)
1.4.2 Sprouting Angiogenesis
1.4.3 Intussusceptive Angiogenesis
1.5 Market by Application
1.5.1 Global Angiongenesis Inhibitors and Stimulators Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Angiongenesis Inhibitors and Stimulators Market Size
2.2 Angiongenesis Inhibitors and Stimulators Growth Trends by Regions
2.2.1 Angiongenesis Inhibitors and Stimulators Market Size by Regions (2014-2025)
2.2.2 Angiongenesis Inhibitors and Stimulators Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Angiongenesis Inhibitors and Stimulators Market Size by Manufacturers
3.1.1 Global Angiongenesis Inhibitors and Stimulators Revenue by Manufacturers (2014-2019)
3.1.2 Global Angiongenesis Inhibitors and Stimulators Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Angiongenesis Inhibitors and Stimulators Market Concentration Ratio (CR5 and HHI)
3.2 Angiongenesis Inhibitors and Stimulators Key Players Head office and Area Served
3.3 Key Players Angiongenesis Inhibitors and Stimulators Product/Solution/Service
3.4 Date of Enter into Angiongenesis Inhibitors and Stimulators Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Angiongenesis Inhibitors and Stimulators Market Size by Type (2014-2019)
4.2 Global Angiongenesis Inhibitors and Stimulators Market Size by Application (2014-2019)

5 United States
5.1 United States Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
5.2 Angiongenesis Inhibitors and Stimulators Key Players in United States
5.3 United States Angiongenesis Inhibitors and Stimulators Market Size by Type
5.4 United States Angiongenesis Inhibitors and Stimulators Market Size by Application

6 Europe
6.1 Europe Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
6.2 Angiongenesis Inhibitors and Stimulators Key Players in Europe
6.3 Europe Angiongenesis Inhibitors and Stimulators Market Size by Type
6.4 Europe Angiongenesis Inhibitors and Stimulators Market Size by Application

7 China
7.1 China Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
7.2 Angiongenesis Inhibitors and Stimulators Key Players in China
7.3 China Angiongenesis Inhibitors and Stimulators Market Size by Type
7.4 China Angiongenesis Inhibitors and Stimulators Market Size by Application

8 Japan
8.1 Japan Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
8.2 Angiongenesis Inhibitors and Stimulators Key Players in Japan
8.3 Japan Angiongenesis Inhibitors and Stimulators Market Size by Type
8.4 Japan Angiongenesis Inhibitors and Stimulators Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
9.2 Angiongenesis Inhibitors and Stimulators Key Players in Southeast Asia
9.3 Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size by Type
9.4 Southeast Asia Angiongenesis Inhibitors and Stimulators Market Size by Application

10 India
10.1 India Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
10.2 Angiongenesis Inhibitors and Stimulators Key Players in India
10.3 India Angiongenesis Inhibitors and Stimulators Market Size by Type
10.4 India Angiongenesis Inhibitors and Stimulators Market Size by Application

11 Central & South America
11.1 Central & South America Angiongenesis Inhibitors and Stimulators Market Size (2014-2019)
11.2 Angiongenesis Inhibitors and Stimulators Key Players in Central & South America
11.3 Central & South America Angiongenesis Inhibitors and Stimulators Market Size by Type
11.4 Central & South America Angiongenesis Inhibitors and Stimulators Market Size by Application

12 International Players Profiles
12.1 Abbott Laboratories
12.1.1 Abbott Laboratories Company Details
12.1.2 Company Description and Business Overview
12.1.3 Angiongenesis Inhibitors and Stimulators Introduction
12.1.4 Abbott Laboratories Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.1.5 Abbott Laboratories Recent Development
12.2 Adnexus Therapeutics
12.2.1 Adnexus Therapeutics Company Details
12.2.2 Company Description and Business Overview
12.2.3 Angiongenesis Inhibitors and Stimulators Introduction
12.2.4 Adnexus Therapeutics Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.2.5 Adnexus Therapeutics Recent Development
12.3 F. Hoffman-La Roche
12.3.1 F. Hoffman-La Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Angiongenesis Inhibitors and Stimulators Introduction
12.3.4 F. Hoffman-La Roche Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.3.5 F. Hoffman-La Roche Recent Development
12.4 Genentech
12.4.1 Genentech Company Details
12.4.2 Company Description and Business Overview
12.4.3 Angiongenesis Inhibitors and Stimulators Introduction
12.4.4 Genentech Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.4.5 Genentech Recent Development
12.5 Amgen
12.5.1 Amgen Company Details
12.5.2 Company Description and Business Overview
12.5.3 Angiongenesis Inhibitors and Stimulators Introduction
12.5.4 Amgen Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.5.5 Amgen Recent Development
12.6 AstraZeneca
12.6.1 AstraZeneca Company Details
12.6.2 Company Description and Business Overview
12.6.3 Angiongenesis Inhibitors and Stimulators Introduction
12.6.4 AstraZeneca Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.6.5 AstraZeneca Recent Development
12.7 Novartis
12.7.1 Novartis Company Details
12.7.2 Company Description and Business Overview
12.7.3 Angiongenesis Inhibitors and Stimulators Introduction
12.7.4 Novartis Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.7.5 Novartis Recent Development
12.8 Pfizer
12.8.1 Pfizer Company Details
12.8.2 Company Description and Business Overview
12.8.3 Angiongenesis Inhibitors and Stimulators Introduction
12.8.4 Pfizer Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.8.5 Pfizer Recent Development
12.9 Chugai Pharmaceutical
12.9.1 Chugai Pharmaceutical Company Details
12.9.2 Company Description and Business Overview
12.9.3 Angiongenesis Inhibitors and Stimulators Introduction
12.9.4 Chugai Pharmaceutical Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.9.5 Chugai Pharmaceutical Recent Development
12.10 EntreMed
12.10.1 EntreMed Company Details
12.10.2 Company Description and Business Overview
12.10.3 Angiongenesis Inhibitors and Stimulators Introduction
12.10.4 EntreMed Revenue in Angiongenesis Inhibitors and Stimulators Business (2014-2019)
12.10.5 EntreMed Recent Development
12.11 Eyetech

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 血管新生阻害剤および刺激剤の世界市場:市場規模・現状・予測(2019-2025)(Global Angiongenesis Inhibitors and Stimulators Market Size, Status and Forecast 2019-2025)]についてメールでお問い合わせはこちらでお願いします。